Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

The neurological syndrome in adults during the 2011 northern German E. coli serotype O104:H4 outbreak.

Magnus T, Röther J, Simova O, Meier-Cillien M, Repenthin J, Möller F, Gbadamosi J, Panzer U, Wengenroth M, Hagel C, Kluge S, Stahl RK, Wegscheider K, Urban P, Eckert B, Glatzel M, Fiehler J, Gerloff C.

Brain. 2012 Jun;135(Pt 6):1850-9. doi: 10.1093/brain/aws090. Epub 2012 Apr 26.

PMID:
22539260
2.

Association between azithromycin therapy and duration of bacterial shedding among patients with Shiga toxin-producing enteroaggregative Escherichia coli O104:H4.

Nitschke M, Sayk F, Härtel C, Roseland RT, Hauswaldt S, Steinhoff J, Fellermann K, Derad I, Wellhöner P, Büning J, Tiemer B, Katalinic A, Rupp J, Lehnert H, Solbach W, Knobloch JK.

JAMA. 2012 Mar 14;307(10):1046-52. doi: 10.1001/jama.2012.264.

PMID:
22416100
3.

Effects of antibiotics on Shiga toxin 2 production and bacteriophage induction by epidemic Escherichia coli O104:H4 strain.

Bielaszewska M, Idelevich EA, Zhang W, Bauwens A, Schaumburg F, Mellmann A, Peters G, Karch H.

Antimicrob Agents Chemother. 2012 Jun;56(6):3277-82. doi: 10.1128/AAC.06315-11. Epub 2012 Mar 5.

4.

Outbreak of hemolytic uremic syndrome caused by E. coli O104:H4 in Germany: a pediatric perspective.

Kemper MJ.

Pediatr Nephrol. 2012 Feb;27(2):161-4. doi: 10.1007/s00467-011-2067-7. Epub 2011 Dec 13.

PMID:
22160440
5.

Treatment of severe neurological deficits with IgG depletion through immunoadsorption in patients with Escherichia coli O104:H4-associated haemolytic uraemic syndrome: a prospective trial.

Greinacher A, Friesecke S, Abel P, Dressel A, Stracke S, Fiene M, Ernst F, Selleng K, Weissenborn K, Schmidt BM, Schiffer M, Felix SB, Lerch MM, Kielstein JT, Mayerle J.

Lancet. 2011 Sep 24;378(9797):1166-73. doi: 10.1016/S0140-6736(11)61253-1. Epub 2011 Sep 2.

PMID:
21890192
6.

[Clinical symptoms, treatment and outcome of EHEC and EHEC-HUS patients treated as in-patients].

Dücker C, Dautel P, Wagner K, Przewozna J, Oehlerking S, Repenthin J, Brüning R, Meyer TN, Faiss S.

Dtsch Med Wochenschr. 2011 Sep;136(36):1770-6. doi: 10.1055/s-0031-1286099. Epub 2011 Aug 31. German.

PMID:
21882131
7.

Management of an acute outbreak of diarrhoea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark: an observational study.

Colic E, Dieperink H, Titlestad K, Tepel M.

Lancet. 2011 Sep 17;378(9796):1089-93. doi: 10.1016/S0140-6736(11)61145-8. Epub 2011 Aug 24.

PMID:
21871657
8.

A German outbreak of haemolytic uraemic syndrome.

Ruggenenti P, Remuzzi G.

Lancet. 2011 Sep 17;378(9796):1057-8. doi: 10.1016/S0140-6736(11)61217-8. Epub 2011 Aug 24. No abstract available.

PMID:
21871656
9.

Prospective genomic characterization of the German enterohemorrhagic Escherichia coli O104:H4 outbreak by rapid next generation sequencing technology.

Mellmann A, Harmsen D, Cummings CA, Zentz EB, Leopold SR, Rico A, Prior K, Szczepanowski R, Ji Y, Zhang W, McLaughlin SF, Henkhaus JK, Leopold B, Bielaszewska M, Prager R, Brzoska PM, Moore RL, Guenther S, Rothberg JM, Karch H.

PLoS One. 2011;6(7):e22751. doi: 10.1371/journal.pone.0022751. Epub 2011 Jul 20.

10.

Origins of the E. coli strain causing an outbreak of hemolytic-uremic syndrome in Germany.

Rasko DA, Webster DR, Sahl JW, Bashir A, Boisen N, Scheutz F, Paxinos EE, Sebra R, Chin CS, Iliopoulos D, Klammer A, Peluso P, Lee L, Kislyuk AO, Bullard J, Kasarskis A, Wang S, Eid J, Rank D, Redman JC, Steyert SR, Frimodt-Møller J, Struve C, Petersen AM, Krogfelt KA, Nataro JP, Schadt EE, Waldor MK.

N Engl J Med. 2011 Aug 25;365(8):709-17. doi: 10.1056/NEJMoa1106920. Epub 2011 Jul 27.

11.

Open-source genomic analysis of Shiga-toxin-producing E. coli O104:H4.

Rohde H, Qin J, Cui Y, Li D, Loman NJ, Hentschke M, Chen W, Pu F, Peng Y, Li J, Xi F, Li S, Li Y, Zhang Z, Yang X, Zhao M, Wang P, Guan Y, Cen Z, Zhao X, Christner M, Kobbe R, Loos S, Oh J, Yang L, Danchin A, Gao GF, Song Y, Li Y, Yang H, Wang J, Xu J, Pallen MJ, Wang J, Aepfelbacher M, Yang R; E. coli O104:H4 Genome Analysis Crowd-Sourcing Consortium.

N Engl J Med. 2011 Aug 25;365(8):718-24. doi: 10.1056/NEJMoa1107643. Epub 2011 Jul 27.

12.

The 2011 Shiga toxin-producing Escherichia coli O104:H4 German outbreak: a lesson in genomic plasticity.

Denamur E.

Clin Microbiol Infect. 2011 Aug;17(8):1124-5. doi: 10.1111/j.1469-0691.2011.03620.x. No abstract available.

13.

Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: a microbiological study.

Bielaszewska M, Mellmann A, Zhang W, Köck R, Fruth A, Bauwens A, Peters G, Karch H.

Lancet Infect Dis. 2011 Sep;11(9):671-6. doi: 10.1016/S1473-3099(11)70165-7. Epub 2011 Jun 22.

PMID:
21703928
14.

Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany.

Frank C, Werber D, Cramer JP, Askar M, Faber M, an der Heiden M, Bernard H, Fruth A, Prager R, Spode A, Wadl M, Zoufaly A, Jordan S, Kemper MJ, Follin P, Müller L, King LA, Rosner B, Buchholz U, Stark K, Krause G; HUS Investigation Team.

N Engl J Med. 2011 Nov 10;365(19):1771-80. doi: 10.1056/NEJMoa1106483. Epub 2011 Jun 22.

15.

Eculizumab in severe Shiga-toxin-associated HUS.

Lapeyraque AL, Malina M, Fremeaux-Bacchi V, Boppel T, Kirschfink M, Oualha M, Proulx F, Clermont MJ, Le Deist F, Niaudet P, Schaefer F.

N Engl J Med. 2011 Jun 30;364(26):2561-3. doi: 10.1056/NEJMc1100859. Epub 2011 May 25. No abstract available.

16.

Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome.

Ståhl AL, Sartz L, Karpman D.

Blood. 2011 May 19;117(20):5503-13. doi: 10.1182/blood-2010-09-309161. Epub 2011 Mar 29.

17.

Therapeutic apheresis in the treatment of hemolytic uremic syndrome in view of pathophysiological aspects.

Bambauer R, Latza R, Schiel R.

Ther Apher Dial. 2011 Feb;15(1):10-9. doi: 10.1111/j.1744-9987.2010.00903.x. Review.

PMID:
21272247
18.

Role of rifampicin in limiting Escherichia coli O157:H7 Shiga-like toxin expression and enhancement of survival of infected BALB/c mice.

Rahal EA, Kazzi N, Kanbar A, Abdelnoor AM, Matar GM.

Int J Antimicrob Agents. 2011 Feb;37(2):135-9. doi: 10.1016/j.ijantimicag.2010.10.009. Epub 2010 Dec 3.

PMID:
21129928
19.

Escherichia coli O157.

Pennington H.

Lancet. 2010 Oct 23;376(9750):1428-35. doi: 10.1016/S0140-6736(10)60963-4. Review.

PMID:
20971366
20.

Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis.

Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, Schwartz J, Weinstein R, Shaz BH; Apheresis Applications Committee of the American Society for Apheresis.

J Clin Apher. 2010;25(3):83-177. doi: 10.1002/jca.20240.

PMID:
20568098

Supplemental Content

Support Center